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Dissertation	Advisor:	Dr.	Ted	Cohen			 	 	 	 												 												Amber	Kunkel	Optimal	use	of	new	and	existing	drugs	for	tuberculosis	control	ABSTRACT		 Tuberculosis	(TB)	recently	surpassed	HIV	as	the	world’s	leading	infectious	killer.		Because	antibiotic	therapy	forms	the	cornerstone	of	TB	control,	prevention,	and	treatment,	it	is	important	to	apply	TB	drugs	in	a	way	that	maximizes	their	potential	benefits	while	minimizing	the	risks	of	resistance.		Here,	I	present	three	modeling	analyses	intended	to	explore	these	tensions	inherent	in	the	use	of	TB	drugs.		 Preventive	therapy	involves	the	use	of	antimicrobials	in	asymptomatic	and	noninfectious	individuals,	and	has	been	applied	to	diseases	ranging	from	TB	to	HIV	to	malaria.		In	my	first	paper,	I	outline	how	population	use	of	preventive	therapy	could	increase,	decrease,	or	have	non-monotonic	effects	on	the	prevalence	of	drug	resistance,	depending	on	the	relative	contributions	of	resistance	acquired	as	a	result	of	preventive	therapy,	resistance	acquired	as	a	result	of	treatment	for	active	disease,	and	transmitted	resistance.				 In	my	second	paper,	I	consider	the	specific	use	of	isoniazid	preventive	therapy	(IPT)	to	prevent	active	TB	among	people	living	with	HIV.	Previous	models	have	suggested	that	widespread	IPT	use	could	increase	the	prevalence	of	drug	resistant	TB	by	providing	a	selective	pressure	in	favor	of	resistant	strains.		In	this	paper,	I	show	that	the	impact	of	IPT	on	drug	resistance	is	highly	dependent	on	the	projected	TB/HIV	epidemic	trends,	and	that	the	risks	of	resistance	are	likely	to	remain	low	for	even	lifelong	IPT	durations	as	long	as	transmission	is	already	declining.	
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Various forms of preventive and prophylactic antimicrobial therapies have been proposed to
combat HIV (e.g. pre-exposure prophylaxis), tuberculosis (e.g. isoniazid preventive therapy), and
malaria (e.g. intermittent preventive treatment). However, the potential population-level e↵ects
of preventive therapy on the prevalence of drug resistance are not well understood. Preventive
therapy can directly a↵ect the rate at which resistance is acquired among those receiving preventive
therapy. It can also indirectly a↵ect resistance by altering the rate at which resistance is acquired
through treatment for active disease and by modifying the level of competition between transmission
of drug-resistant and drug-sensitive pathogens. We propose a general mathematical model to
explore the ways in which preventive therapy can a↵ect the long-term prevalence of drug resistance.
Depending on the relative contributions of these three mechanisms, we find that increasing the level
of coverage of preventive therapy may result in increases, decreases, or non-monotonic changes in the
overall prevalence of drug resistance. These results demonstrate the complexity of the relationship
between preventive therapy and drug resistance in the population. Care should be taken when
predicting population-level changes in drug resistance from small pilot studies of preventive therapy
or estimates based solely on its direct e↵ects.
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Introduction
Preventive and prophylactic infectious disease therapies (we will refer to both collectively as
preventive therapy, PT) involve the use of chemotherapeutic agents in asymptomatic and nonin-
fectious individuals, with the goal of preventing future symptoms and infectiousness. PT may be
applied to individuals who are either uninfected or latently infected with a given pathogen. For
example, whereas isoniazid preventive therapy for TB can prevent disease progression in latently
infected individuals [1][2], pre-exposure prophylaxis for HIV is intended solely for use in uninfected
individuals [3]. Some interventions may include aspects of both treatment and preventive therapy;
for example, intermittent preventive treatment for malaria involves a full course of antimalarial
treatment applied irrespective of infection status [4].
Because PT prevents development of infectiousness as well as symptoms, PT has been pro-
posed as an element of public health strategies aimed at reducing the burden of TB, HIV, and
malaria [4][5][6]. However, such strategies have often been controversial, with concerns about drug
resistance forming one major barrier to implementation [7][8]. When the chemotherapeutic agents
that are used for prevention are also needed for treatment, any drug resistance produced or am-
plified as a result of PT may undermine future control e↵orts. Simulation models intended to
assess the potential e↵ects of PT on the prevalence of drug resistance have produced sometimes
inconsistent results [9]. For example, Supervie et al. [10][11] predicted that rolling out pre-exposure
prophylaxis in Botswana would reduce the prevalence of drug resistant HIV, whereas Abbas et
al. [12][13] predicted that a similar programme in South Africa would increase the prevalence of
drug resistant HIV.
Models intended to predict the e↵ects of specific PT programmes tend to be fairly complex, with
states and parameters chosen to reflect the natural history of the disease of interest, the operational
details of the proposed intervention, and the e cacy of the available drug. While this complexity
may improve the predictive accuracy of each individual model, it can complicate attempts to explain
di↵erences in their predictions [9][11][13]. In this paper, we create a simplified, general model of PT
with the goal of better understanding the ways in which PT could alter the population prevalence
of drug resistance. We show that increasing PT coverage can have qualitatively di↵erent e↵ects
on the prevalence of drug resistance depending on the relative importance of resistance acquired
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as a result of preventive therapy, resistance acquired as a result of treatment, and the competitive
fitness of drug resistant strains.
Methods
We developed a simple mathematical model to demonstrate the ways in which preventive therapy
may alter the prevalence of drug resistance. Mathematical modelling provides a way to formally
encode our understanding of the individual-level e↵ects of preventive therapy, some of which may
lead to drug resistance. Furthermore, mathematical modelling creates a conceptual framework to
explore how the e↵ects of preventive therapy on drug resistance in the population may extend
beyond its immediate recipients.
Model Structure: Disease Course
A description of the states and parameters used in our model is given in Table 1.1. Figure 1.1
displays the structure of this compartmental model, with the health states and transitions among
individuals not receiving PT on the left-hand side and and among individuals receiving PT on the
right-hand side. We focus first on individuals not receiving PT, shown on the left. Although this
portion of the figure shows the rates at which individuals may begin and end preventive therapy
(PT states shown in dotted boxes), it does not display transitions between PT states.
Within the model, an individual may be infected by pathogen phenotypes that are either drug
sensitive (DS, indicated in the diagram by a subscript S) or drug resistant (DR, indicated in
the diagram by a subscript R), but not by both simultaneously. Not allowing for mixed infections
greatly simplifies our model, but introduces strong assumptions about competition between strains,
the implications of which are considered in the Discussion. Susceptible (S) persons who are infected
enter latency with either the DS strain (LS) or the DR strain (LR), depending on the source of
the infection. Latently infected individuals may be superinfected and move to the latent state
characterized by the drug sensitivity pattern of the most recently infecting strain. We assume the
degree of susceptibility to reinfection x does not depend on the identity of the initial or reinfecting
strain. We do allow the risks of infection and progression to active disease to di↵er based on the
drug sensitivity of the infecting strain, reflecting the potential fitness costs of resistance.
All actively infected individuals within our model, including those on treatment, contribute to
the overall force of infection. We assume that infectious individuals cannot be reinfected and cannot
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recover except by treatment. We allow individuals receiving treatment for DS disease to acquire
resistance at rate a. We assume such acquired resistant cases are immediately detected and started
on treatment for DR disease, which we assume has a lower cure rate than treatment for DS disease.
We do not allow for disease-induced mortality or explicitly encode for treatment failure, though
the latter may be incorporated into the treatment cure rate. Once cured, individuals revert to a
recovered (R) state exhibiting the same level of immunity as that experienced by latently infected
individuals.
Though we omit arrows representing mortality from Fig 1.1, we assume a constant mortality rate
from each compartment and a constant population size. All individuals enter the model susceptible
to infection and not on PT. Because we assume a fixed population size, we express all states in
terms of proportion of the population.
Model Structure: Preventive Therapy
The right-hand side of Fig 1.1 displays the portion of our model pertaining to individuals
receiving preventive therapy. This portion of the figure again displays the rates at which individuals
may begin or end preventive therapy (non-PT states shown in dotted boxes), but omits arrows
indicating the transitions between states of individuals not receiving PT. We allow for individuals
who are uninfected, latently infected, or actively infected to potentially receive PT. Uninfected
individuals begin PT at rate f and cease therapy at rate w. Latently infected individuals begin
PT at rate fl and cease therapy at rate w. We allow the rates at which uninfected and latently
infected individuals initiate PT to di↵er, as the specific targeting of PT depends on the disease and
drug of interest. Pre-exposure prophylaxis for HIV, for example, is intended solely for uninfected
individuals [3], whereas isoniazid preventive therapy is typically targeted to individuals with latent
TB infection [1][2]. We assume that the PT initiation rate is the same for both DS and DR latently
infected individuals, assuming that the resistance phenotype of the infecting strain is not known
during latency. Actively infected individuals may also receive PT within our model. Though PT is
generally not intended for such individuals (except when the same drug is applied as both treatment
and prevention, e.g. intermittent preventive treatment for malaria [4]), individuals may progress
from latent to active infection while receiving PT (rate kPTS ) or initiate PT during active disease
as a result of imperfect screening (rate fi). We assume that the PT start rate is the same for
both DS and DR actively infected individuals, assuming the infection is not recognized prior to PT
10
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Figure 1.1: Left: All states and transitions involving individuals not on preventive therapy (solid
boxes), with transitions on and o↵ PT shown via links to on-PT states (dashed boxes). Right: All
states and transitions involving individuals on preventive therapy (solid boxes), with transitions o↵
and on PT shown via links to o↵-PT states (dashed boxes).
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Table 1.1: Model states and parameters
State Name Description (All States: Proportion of Population)
S Susceptible Uninfected, negative infection history
LS DS Latent Latently infected with DS strain
LR DR Latent Latently infected with DR strain
IS DS Actively Infected Infectious with DS strain, not on treatment
IR DR Actively Infected Infectious with DR strain, not on treatment
TS DS Treated Infectious with DS strain, on treatment
TR DR Treated Infectious with DR strain, on treatment
I⇤S Total DS Infectious Sum of DS infectious states: IS + I
PT
S + TS
I⇤R Total DR Infectious Sum of DR infectious states: IR + I
PT
R + TR
R Recovered Uninfected, positive infection history
Parameter Name Description
 S DS transmission parameter # DS e↵ective contacts per susceptible per unit time
 R DR transmission parameter # DR e↵ective contacts per susceptible per unit time
kS DS progression rate Rate of progression from DS latent to DS actively infected
kR DR progression rate Rate of progression from DR latent to DR actively infected
c Case detection rate Rate at which actively infected individuals begin treatment
rS DS recovery rate Rate of recovery from DS treated to recovered
rR DR recovery rate Rate of recovery from DR treated to recovered
a Treated resistance rate Rate resistance is acquired due to treatment
al PT latent resistance rate Rate resistance is acquired by DS latents on PT
ai PT active resistance rate Rate resistance is acquired by DS actively infecteds on PT
x Reinfection susceptibility Susceptibility retained after initial infection
w PT exit rate Reciprocal of average duration of PT
f PT uninfected start rate Start rate of PT for uninfected individuals
fl PT latent start rate Start rate of PT for latently infected individuals
fi PT active start rate Start rate of PT for actively infected individuals
Superscript Name Description
PT Preventive therapy State/parameter refers to individuals receiving PT
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initiation. We assume that actively infected individuals cease preventive therapy routinely, at rate
w, or upon initiation of treatment, at the same case detection rate c as for individuals not receiving
PT.
The health states for individuals receiving PT are similar to those described for individuals not
receiving PT. We assume PT reduces the rate at which uninfected and latently infected individuals
are infected with the DS strain ( PTS <  S), the rate at which DS latently infected individuals
progress to active disease (kPTS < kS), or the rates of both infection and progression with the DS
strain. Although we assume that preventive therapy has no direct e↵ect on infection or progression
with the DR strain, it may a↵ect the probability of progression with the DR strain by changing
the probability of reinfection with the DS strain. We allow DS latently infected individuals to
acquire resistance as a result of preventive therapy at rate al and DS actively infected individuals
at rate ai. We assume PT does not cure or reduce the infectiousness of individuals with active
infection. We also assume that individuals cannot receive PT and treatment simultaneously, but
treated individuals again become eligible for PT upon recovery. Throughout our analysis, we do
not track which individuals receive PT and thus assume that the same individuals may receive
multiple courses of PT.
Outcome Measures
Throughout our analysis, we focus on the equilibrium behaviour of the model. Doing so simplifies
our analysis by removing its dependence on the initial model conditions. We begin each of our
analyses in the absence of PT (setting the PT start rates f = fl = fi = 0). For each of our
analyses, we choose a parameter set such that, in the absence of PT, the equilibrium prevalence of
the DS strain is nonzero and the basic reproductive number of the DR strain exceeds 1. Because
we allow for acquired resistance, the former requirement implies that the equilibrium prevalence of
the DR strain is also nonzero in the absence of PT (i.e. there is no DS only equilibrium). The latter
implies that the equilibrium prevalence of the DR strain will remain nonzero even if the equilibrium
prevalence of the DS strain does not.
Holding this parameter set fixed, including the rates of case detection and treatment for active
disease, we run a series of simulations at progressively higher values of the PT initiation rate. For
the purpose of our simulations, we assume the PT start rates among uninfected, latently infected,
and infectious individuals are proportional throughout, with fl = f and fi = f/10, and thus
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refer to the PT start rate using the single parameter f . For each individual simulation, we fix
the value of the PT initiation rate, run the model to equilibrium (i.e. until changes in population
composition between time steps become negligible), and record the resulting prevalence of the DR
strain. We repeat the simulation process for incrementally increasing values of f until the DS strain
is eliminated (the equilibrium prevalence of the DS strain equals 0), still holding the PT initiation
rate constant within each individual simulation. Because we do not allow DR strains to revert to
DS, such elimination of the DS strain is possible in our model even when the equilibrium prevalence
of the DR strain remains nonzero.
All of the results provided are based on model simulations created using the R di↵erential
equation solver “ode” within package deSolve.
Results
In our model, increasing the intensity of preventive therapy directly a↵ects the amount of re-
sistance acquired through preventive therapy. It also indirectly a↵ects the amount of resistance
acquired through treatment for active disease and the competitive transmission advantage a↵orded
to DR strains. We find that the combined e↵ects of these mechanisms can result in increasing,
decreasing, and non-monotonic relationships between the intensity of PT coverage and DR preva-
lence. Throughout the results, we use the word “treatment” to refer solely to treatment for active
disease.
PT coverage and resistance acquired through PT
In our model, preventive therapy may lead directly to acquired resistance among individuals
latently or actively infected with the DS strain. To demonstrate how it may do so, Fig 1.2 provides
a focused view of the relevant states and transitions from Fig 1.1. Unbolded arrows in Fig 1.2
show the transitions that may lead to individuals latently or actively infected with the DS strain
receiving PT. Bolded arrows show the acquisition of resistance among such individuals as a result
of PT. If no individuals are to acquire resistance as a result of preventive therapy, one of the
following scenarios must apply: 1) no individuals with active or latent infection ever receive PT,
2) no individuals with active infection ever receive PT, and PT never results in acquired resistance
among latently infected individuals, or 3) PT never results in acquired resistance among latently
or actively infected individuals. The first scenario assumes that PT is intended only for uninfected
14
individuals, that screening for latent and active infection prior to PT initiation is perfect (fi = 0
and fl = 0), and that adherence and drug e cacy are su ciently high that individuals receiving
PT never become infected ( PTS = 0). The second scenario assumes that PT never selects for
sporadically occurring resistant mutants among individuals with latent infection (al = 0), that
screening for active infection prior to PT initiation is perfect (fi = 0), and that adherence and
drug e cacy are su ciently high that individuals receiving PT never progress from latent to active
infection (kPTS = 0). The third scenario assumes that PT is incapable of selecting for resistance
at the individual level among both latently and actively infected individuals (al = 0 and ai = 0).
Even well-functioning preventive therapy programmes are unlikely to meet these stringent criteria,
and thus it is reasonable to expect that some individuals will directly acquire resistance as a result
of preventive therapy.
When we assume that some or all of these parameters are nonzero, reflecting the vast majority
of real-world PT applications, the relationship between PT coverage and resistance acquired as a
result of PT is shown in Fig 1.3. The level of resistance acquired through PT is a function of the
number of DS actively and latently infected individuals receiving PT (aiIPTS + alL
PT
S ). When PT
coverage is low and insu ciently able to control the epidemic, increasing PT coverage increases
the number of latently and actively infected individuals receiving PT and thus the number of
people who acquire resistance as a result of preventive therapy. When PT coverage is high and
better able to control the epidemic, increasing PT coverage decreases the number of people who
acquire resistance as a result of preventive therapy (similar to an e↵ect described in [14]). Under
such scenarios, although increasing the PT initiation rate still increases the total number of people
receiving PT, the resulting reduction in the force of DS infection is su cient to decrease the number
of people receiving PT who have latent or active DS infection. Because only DS infected individuals
are at risk of acquiring resistance as a result of PT, this results in a reduction of the rate at which
resistance is acquired as a result of PT.
PT coverage and resistance acquired through treatment
As is seen in Fig 1.1, our model allows individuals receiving treatment for active DS disease
(TS) to acquire resistance at rate a. Increasing the coverage of PT in the population decreases the
number of people infected with the DS strain, and thus decreases the number of people who acquire

























Figure 1.2: Subset of the model representing the rates at which individuals with latent or active
DS disease receiving preventive therapy (LPTS and I
PT
S , respectively) acquire resistance (bold) and
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Figure 1.3: The relationship between PT start rate f and the rate at which resistance is acquired through
PT (aiIPTS +alL
PT
S ) at equilibrium. Parameters for this figure: µ = 0.02, rR = 1, rS = 2, c = 1, kR = 1, kS =
1.5, S = 2, R = 1, x = 1, a = 0.3, ai = 0.5, al = 0.1, w = 0.1, PTS = 0, k
PT
S = 0.
PT coverage and transmission of the DR strain
Our model assumes high levels of competition for susceptible hosts between strains, as we do not
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Figure 1.4: The relationship between PT start rate f and the rate at which resistance is acquired through
treatment for DS disease (aTS) at equilibrium. Parameters for this figure are the same as those for Fig 1.3.
advantage to DR strains through two distinct mechanisms. First, increasing PT coverage increases
the probability that an individual latently infected with the DR strain will progress to active
DR infection. This relationship is a result of our assumption that DR latently infected individuals
could potentially be “rescued” from progressing to DR disease by superinfection with the DS strain.
As PT coverage increases, DR latently infected individuals are increasingly protected from such
superinfection and are therefore more likely to progress with their DR strain. Second, increasing
PT coverage increases the proportion of DR uninfected individuals who are susceptible to the DR
strain. In our model, the proportion of all individuals who are susceptible to the DR strain is given
by S+xLS +xR+SPT +xLPTS +xR
PT , which depends on the proportion of people uninfected by
the DR strain, the proportion of people with active DS infection, and the level of immunity a↵orded
by initial infection. To obtain the proportion of DR uninfected individuals who are susceptible to
DR infection, we divide this by the total proportion of individuals not actively or latently infected
with the DR strain (S + R + LS + SPT + RPT + LPTS + IS + I
PT
S + TS). Increasing PT coverage
reduces the number of persons with active DS infection, and therefore increases the proportion of
DR uninfected individuals who are susceptible to the DR strain. These two e↵ects are discussed in
more detail in the appendix.
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The e↵ective reproductive number of the DR strain is a composite measure that allows us to
assess the combined e↵ects of these mechanisms on the competitive fitness of the DR strain. The
e↵ective reproductive number shows the number of secondary infectious cases produced by a single
infectious individual over the course of their infectious period. As opposed to the basic reproductive
number R0, which assumes a wholly susceptible population, the e↵ective reproductive number at a
given time point depends on the susceptibility pattern of the population at that point in time. In
a single strain model, the e↵ective reproductive number at equilibrium is equal to 1. In our model,
however, the number of DR infected individuals is boosted by acquired resistance, and therefore the
DR strain may coexist with the DS strain in the population even when the e↵ective reproductive
number of the DR strain is below 1.
Fig 1.5 shows how the e↵ective reproductive number of the DR strain at equilibrium changes
as PT coverage increases. At low PT coverage levels, the DR e↵ective reproductive number is less
than 1, indicating that acquired resistance is necessary for the persistence of the DR strain in the
population. As PT coverage increases, the reproductive fitness of the DR strain increases as well.
When PT coverage is su ciently high, the DR e↵ective reproductive number reaches 1, indicating
that resistance has become self-sustaining and the DR strain has overtaken the DS strain in the
population.
Composite e↵ects of PT coverage on DR prevalence
Table 1.2: Summary of mechanisms through which PT may a↵ect the prevalence of drug resistance. The
proportion susceptible to the DR strain and the reproductive number of the DR strain are discussed in more
detail in the appendix.
Source of Influence Driven by E↵ect on DR Prevalence for
Resistance Health States Parameters Low PT Coverage High PT Coverage
PT
DS infected Rate resistance acquired " #
on PT (LPTS , I
PT
S ) on PT (al, ai)
Treatment DS Treated (TS)
Rate resistance acquired # #
on treatment (a)
Transmission
Susceptible to Reproductive number " "
DR strain of DR strain
Table 1.2 summarises the ways in which each of the resistance mechanisms outlined above will
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Figure 1.5: The relationship between PT start rate f and the e↵ective reproductive number of the DR
strain at equilibrium. Calculations are given in the appendix. Parameters for this figure are the same as
those for Fig 1.3.
acquired due to treatment, it can also increase the competitive transmission advantage of circu-
lating DR strains, and its e↵ects on the rate of resistance acquired due to PT are non-monotonic.
Furthermore, in our model as in reality, none of these mechanisms exist in isolation. Rather, in-
creasing PT coverage acts simultaneously on the rate at which resistance is acquired through PT,
the rate at which resistance is acquired through treatment, and the competitive fitness of the DR
strain. In Fig 1.6 we show that the interactions between these mechanisms are su cient to produce
a range of qualitatively distinct relationships between PT coverage and equilibrium DR prevalence.
Though the behaviours shown in this figure occur with varying frequencies and are not necessarily
exhaustive, they demonstrate the complexity of the changes in DR prevalence that may result from
PT.
All of the subplots in Fig 1.6 were created using the same model of preventive therapy under
di↵erent sets of parameters. The parameters used for each subplot are shown in the figure caption.
In Subplot A, DR prevalence increases monotonically with PT coverage. The parameters used to
produce this subplot were the same as those used to create the figures for the previous sections. In
Subplot B, DR prevalence increases with PT coverage when PT coverage is low, but decreases with
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increasing PT coverage if PT coverage exceeds a threshold value. To create this subplot, we lowered
the transmission parameter for the DR strain  R. This decrease in the transmissibility of the DR
strain allows acquisition of resistance through PT and treatment to play a larger role in changing
DR prevalence. In Subplot C, DR prevalence decreases monotonically with increasing PT coverage.
To create this subplot, we lowered the transmission parameter of the DR strain as in subplot B
and assumed that no resistance was acquired as a result of preventive therapy, allowing acquisition
of resistance by treatment alone to become the major driver of DR prevalence. Finally, in Subplot
D, DR prevalence decreases with increasing PT coverage when PT coverage is low, but increases
with increasing PT coverage if PT coverage exceeds a threshold value. To create this subplot, we
lowered the reinfection susceptibility of latently infected and recovered individuals, assumed no
resistance acquired as a result of preventive therapy, and assumed PT did not a↵ect infection with
the DS strain (i.e. that it only a↵ected disease progression). The resulting U-shaped curve indicates
that, at low coverage levels, PT primarily influences resistance acquired due to treatment for active
disease, whereas at high coverage levels, PT exerts more influence by allowing greater transmission
of the DR strain. This relationship may reflect the fact that lowering the progression rate a↵ects the
prevalence of latent DS infection di↵erently than the rate of active DS infection, complicating the
association between the prevalence of DS disease and the number of people susceptible to infection
with the DR strain. Note that the absolute changes in DR prevalence in this subplot are small;
nevertheless, this shape further reflects the complexity of the ways in which PT may cause changes
in DR prevalence.
Discussion
Mathematical models of varying complexity have been constructed to predict the e↵ects of
pre-exposure prophylaxis for HIV [15][12][10], isoniazid preventive therapy for TB [16][17][18], and
intermittent preventive treatment for malaria [19][20] on the prevalence of drug resistance. Here, we
have used a more general model to provide an overall view of the ways in which preventive therapy
may influence the prevalence of drug resistance and the anticipated directions of these e↵ects.
First, we have described the relationship between PT coverage and the amount of resistance
acquired directly as a result of PT. Previous models have demonstrated particular sensitivity to
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Figure 1.6: Relationship between PT start rate f and DR prevalence (IR + IPTR + TR) at equilibrium.
Parameters for Subplot A are the same as those from Figs 1.3, 1.4, and 1.5: µ = 0.02, rR = 1, rS = 2, c =
1, kR = 1, kS = 1.5, S = 2, R = 1, x = 1, a = 0.3, ai = 0.5, al = 0.1, w = 0.1, PTS = 0, k
PT
S = 0.
Parameters for Subplot B: same as for Subplot A, except  R = 0.55. Parameters for Subplot C: same as
for Subplot A, except  R = 0.55, ai = 0, al = 0. Parameters for Subplot D: same as for Subplot A, except
x = 0.4, ai = 0, al = 0, PTS = 2. The same range of PT start rates is shown for each subplot, though this
range is insu cient to cause elimination of the DS strain in subplot D.
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PT coverage is low, increasing PT coverage increases the amount of resistance acquired as a result
of PT. When PT coverage is high, however, further increasing PT coverage decreases the amount of
resistance acquired as a result of PT, resulting in an inverted U-shaped curve between PT coverage
and resistance acquired from PT. A similar relationship has been described between drug pressure
and the rate of resistance in the setting of treatment for active disease [14]. Notably, this resistance
mechanism is not a necessary consequence of the beneficial e↵ects of PT. The number of people who
acquire resistance as a result of PT may be reduced by limiting the number of infected individuals
started on PT (e.g. through better screening programmes), the number of individuals receiving PT
who develop latent or active infection (e.g. through better adherence or more e↵ective PT drugs),
and the rate at which infected individuals on PT acquire resistance (e.g. through drugs or drug
combinations more similar to those used for treatment).
Second, we have shown that increasing PT coverage decreases the amount of resistance acquired
as a result of treatment for active disease. This relationship occurs because PT decreases the
number of individuals with active DS disease. We would expect a similar relationship to hold for
non-therapeutic interventions that do not exclusively target DS disease, such as condom use in the
setting of HIV.
Third, we have demonstrated that increasing PT coverage provides a selective advantage to
circulating DR strains. We have found that increasing PT coverage increases the e↵ective repro-
ductive number of the DR strain, which is consistent with predictions and observations for vaccines
targeting specific disease strains [22][23] and previous PT modelling papers that have used strain
competition to explain predicted increases in DR prevalence [17][18]. Increasing the intensity of PT
coverage increases the e↵ective reproductive number of the DR strain by increasing the probability
that a DR latently infected individual will progress to active DR infection (before reinfection with
the DS strain) and by increasing the proportion of the DR uninfected population that is susceptible
to infection with the DR strain.
Finally, we have shown that PT may have a wide range of e↵ects on overall DR prevalence,
depending on the interaction of these three mechanisms. Specifically, we have provided examples
of increasing, decreasing, U-shaped, and inverted U-shaped relationships between PT intensity
and equilibrium DR prevalence resulting from our model. These four shapes are not necessarily
exhaustive, but demonstrate that the relationship between PT coverage and DR prevalence may
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di↵er qualitatively depending on the disease and drug in question. In particular, predictions of the
e↵ects of PT on drug resistance are sensitive to a number of properties of the system: the rate at
which resistance is acquired as a result of PT, the rate at which resistance is acquired as a result
of treatment, the fitness costs of resistance on disease transmissibility, the mechanisms of PT, and
the rate of reinfection. Reliable estimates of these parameters are needed to accurately predict
the e↵ects of proposed PT programmes on DR prevalence. Our estimates are also sensitive to the
assumption that individuals cannot be reinfected throughout their infectious periods, illustrating
the importance of understanding within-host strain competition when predicting the population-
level e↵ects of PT.
Understanding how each of these factors contribute to the relationship between preventive ther-
apy and drug resistance may aid in the interpretation of models with di↵ering predictions about
the e↵ects of PT on drug resistance. For example, our analysis sheds some additional light on the
observations made by Abbas et al. [13] on the sources of di↵erence in the model predictions of
Supervie et al. [10] and Abbas et al. [12]. Abbas et al. [13] re-created both models to explore the
reasons for contrasting conclusions about the potential relationship between PrEP and HIV drug
resistance in sub-Saharan Africa. They suggest that a low value of R0 contributed to PrEP decreas-
ing the prevalence of drug resistance in [10], which accords with our demonstration that although
preventive therapy provides a competitive advantage to DR strains, it may still reduce the overall
prevalence of drug resistance when the transmissibility of the DR strain is low and resistance is
driven primarily by acquisition. Similarly, their observation that the di↵erences between the two
models could be partially explained by di↵ering PrEP coverage rates is supported by our finding
that the e↵ects of increasing PT coverage may be non-monotonic. The authors also acknowledge
that resistance in the population occurs as a result of transmission and treatment (i.e. antiretroviral
therapy) as well as PrEP; as we have shown, the e↵ects of preventive therapy on drug resistance
cannot be distilled to its e↵ects on resistance acquired through PT alone.
We have presented a general model that may not perfectly reflect the natural history of any
particular infection. Though in reality the specific action and targeting of PT varies depending
on the disease and drug of interest, we assume PT protects both susceptible and latently infected
individuals from active DS disease. Our assumption of no latent or active mixed infections en-
codes a high level of competition between strains for susceptible hosts, the biological plausibility
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of which will depend on the disease of interest. Other models have demonstrated that allowing
for mixed infections may either heighten or mitigate the e↵ective degree of competition between
strains depending on assumptions of how strains compete within and between hosts [24][25][26][27].
If we could assume DS and DR strains are perfectly non-competing, changing PT coverage may
not a↵ect the e↵ective reproductive number of the DR strain; however, we expect most pathogens
to exhibit some level of within-strain competition and therefore qualitative behaviours similar to
those described here. In addition to the assumption of no mixed infections, we assume a binary
designation of drug resistance that may not accurately represent the accumulation of resistance
mutations within a single host. Furthermore, we do not allow DR strains to revert to DS, though
this behaviour has been demonstrated for pathogens including HIV [28]. We assume that the ef-
fects of PT on disease progression cease immediately after PT is removed, and do not allow PT to
increase the cure rate or reduce the infectiousness of infectious individuals (as might occur if the
drugs used for PT are similar to those used for treatment). Similarly, we assume that PT has no
direct e↵ects on immunity to future infection. Finally, we focus our analysis on the e↵ects of PT on
drug resistance at equilibrium, even though policymakers may be most interested in its short-term
e↵ects.
Nevertheless, we have provided a systematic account of both direct and indirect mechanisms
through which PT may a↵ect DR prevalence. Depending on the relative contributions of these
resistance mechanisms, raising PT coverage could have increasing, decreasing, or non-monotonic
e↵ects on long-term DR prevalence. Because these relationships may be non-monotonic, care should
be taken when extrapolating the e↵ects of small PT programmes to larger e↵orts.
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APPENDIX S1
How could preventive therapy a↵ect the prevalence of drug resistance? Causes and consequences
Amber Kunkel, Caroline Colijn, Marc Lipsitch, Ted Cohen
Equations
The states and parameters used here are the same as those described in Table 1.1 in the main
text.
S˙PT = fS   wSPT    PTS (IS + IPTS + TS)SPT    R(IR + IPTR + TR)SPT   µSPT
L˙S =  S(IS + I
PT
S + TS)(S + xLR + xR)  x R(IR + IPTR + TR)LS   (kS + µ+ fl)LS + wLPTS
L˙R =  R(IR + I
PT
R + TR)(S + xLS + xR)  x S(IS + IPTS + TS)LR   (kR + µ+ fl)LR + wLPTR
L˙PTS =  
PT
S (IS + I
PT
S + TS)(S
PT + xLPTR + xR
PT )  x R(IR + IPTR + TR)LPTS
  (kPTS + µ+ w + al)LPTS + flLS
L˙PTR =  R(IR + I
PT
R + TR)(S
PT + xLPTS + xR
PT )  x PTS (IS + IPTS + TS)LPTR
  (kR + µ+ w)LPTR + flLR + alLPTS
I˙S = kSLS   (c+ µ+ fi)IS + wIPTS










S   (c+ µ+ w)IPTR + fiIR
T˙S = c(IS + I
PT
S )  (rS + µ+ a)TS
T˙R = c(IR + I
PT
R )  (rR + µ)TR + aTS
R˙ = wRPT   fR+ rSTS + rRTR   x S(IS + IPTS + TS)R  x R(IR + IPTR + TR)R  µR
R˙PT = fR  wRPT   x PTS (IS + IPTS + TS)RPT   x R(IR + IPTR + TR)RPT   µRPT
S = 1  TS   TR   IS   IR   IPTS   IPTR   LS   LR   LPTS   LPTR  R RPT   SPT
Calculating DR E↵ective Reproductive Number
This section refers to states and parameters described in Table 1.1 in the main text. The e↵ective
reproductive number is the number of secondary infectious cases produced by a single infectious
individual over the course of their infectious period. We derived the e↵ective reproductive number
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We walk through each of the individual components of this equation below.  R is the transmis-
sion parameter for the DR strain, as described in the main text.
D, the average duration of infectiousness with the DR strain, is the sum of two terms: 1) the
average length of stay in the untreated infectious compartment and 2) the average length of stay
in the treated infectious compartment given that the individual initiates treatment prior to death.













P 0, the probability of progressing from latent to active disease for individuals not on preventive
therapy at the time of infection, is the sum of the probability of progressing before leaving LR, the
probability of starting preventive therapy and then progressing before leaving LPTR , the probability
of starting preventive therapy and then stopping preventive therapy and then progressing before


















































where D0 is the rate of exit from LR
D0 = kR + µ+  S(IS + I
PT
S + TS) + fl
and DPT is the rate of exit from LPTR
DPT = kR + µ+  
PT
S (IS + I
PT
S + TS) + w.
This expression for P 0 captures all of the possible paths from the latent state to the infectious
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state and hence captures the total probability of progression from latency to active DR disease. If




















We can similarly derive the expression for PPT , the probability of progressing from latent to




















Finally, ✓0R is the fraction of individuals who are susceptible to infection with the DR strain and
not currently on PT:
✓0R = S + xR+ xLS
and ✓PTR is the fraction of individuals on PT who are susceptible to infection with the DR strain:
✓PTR = S
PT + xRPT + xLPTS .
Individuals already infected with the DR strain are not included here, even though they may be
reinfected with the DR strain, because they do not change states upon reinfection.
DR E↵ective Reproductive Number Components
Changing the coverage of preventive therapy changes the DR e↵ective reproductive number in
two ways: by a↵ecting the proportion of people infected with the DR strain who progress to active
DR disease, and by a↵ecting the proportion of the population that is susceptible to the DR strain.
Here we show how each of these components are a↵ected by changing PT coverage, using notation
defined earlier in the appendix and in Table 1.1 in the main text.
The proportion of people infected with the DR strain who progress to active DR infection
depends on the DS infection rate, which itself depends on the proportion of the population receiving
preventive therapy. To produce a population average, we used the formula
P =







The results are shown in Supplemental Figure S1.1. The proportion of DR infected persons who
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Figure S1.1: The relationship between PT start rate f and the proportion of people infected with the DR
strain who progress to active DR infection. Parameters for this figure are the same as those for Fig 1.3 in
the main text.
The proportion of people susceptible to the DR strain depends on the number of people unin-
fected with the DR strain without active DS infection and the level of immunity a↵orded by initial
infection. To remove the e↵ects of changing DR prevalence, we show here the proportion of DR









The results are shown in Supplemental Fig S1.2. The proportion of DR uninfected individuals who
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Figure S1.2: The relationship between PT start rate f and proportion of DR uninfected persons susceptible



























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































We include four TB resistance types: drug susceptible (DS), isoniazid monoresistant (INH-
R), rifampicin monoresistant (RMP-R), and multi-drug resistant (MDR). Each individual is
initially infected with only one TB strain. From the latent compartment, individuals may be
reinfected with any strain. Upon reinfection, the individual either immediately transitions
to active disease with the infecting strain, or enters a latent state in which both strains are
present. Theoretically, this process may be repeated any number of times, so that a single
latently infected person could contain any number of strains with any pattern of resistance.
We simplify the analysis by assuming the progression to active disease acts as a bottleneck,
with only the dominant strain surviving and causing disease (similar to [?]). We assume
the dominant strain is probabilistically determined at the time of each infecting event. We
also assume that IPT is the only condition under which a non-dominant strain may become
dominant, and that this will only occur in individuals with both dominant isoniazid sensitive
and non-dominant isoniazid resistant strains. At any given time, each person has at most two
strains of interest: the strain that will dominate under normal conditions, and (potentially) a
second strain that will dominate under the selective pressure of IPT. We therefore restrict our
latent states to eight resistance classes (see Table 1) and our active states to four resistance
classes representing the four strain types.
Table 1: Description of TB Latency States




DS INH-r RMP-r MDR
DS Ls - - -
INH-r Lsi Li Lri -
RMP-r - - Lr -
MDR Lsm - Lrm Lm
1.1.4 Model Entry
To simplify the model, we explicitly model adults only. People enter the model at age 15,
and are assumed to be HIV-negative. We assume that people below age 15 do not contribute
to the force of TB infection, or measured TB incidence and prevalence; these assumptions
reflect the low probability of smear positivity among pediatric TB cases. Individuals may
enter the model either TB-susceptible or latently infected with at most one TB strain. The
probability of being TB-susceptible at model entry is assumed to be equal to the probability
of zero infection events, where the number of infections follows a Poisson distribution with
parameter derived by integrating over the annual risk of infection for the previous 15 years.
For simplicity, individuals entering the model are assumed to be infected with at most one
strain, with proportions of strain types determined by the relative force of infection of each
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# R code containing model equations  
# Does not include time dependent parameters 
# Can by run via R function "dede" from package deSolve 
 
IPT_model_mixed <- function(times, yinit, pars) { 
  
 with(as.list(c(yinit,pars)), { 
 
  ##################################### 
  # Sums 
  ##################################### 
   
  Ln = Ln_s + Ln_si + Ln_sm + Ln_r + Ln_ri + Ln_rm + Ln_i + Ln_m; 
  Lu = Lu_s + Lu_si + Lu_sm + Lu_r + Lu_ri + Lu_rm + Lu_i + Lu_m; 
  Lipt = Lipt_s + Lipt_i + Lipt_r + Lipt_m; 
  Ld = Ld_s + Ld_si + Ld_sm + Ld_r + Ld_ri + Ld_rm + Ld_i + Ld_m; 
   
  In = In_s + In_r + In_i + In_m; 
  Iu = Iu_s + Iu_r + Iu_i + Iu_m; 
  Iipt = Iipt_s + Iipt_r + Iipt_i + Iipt_m; 
  Id = Id_s + Id_r +Id_i + Id_m; 
   
  T1n = T1n_s + T1n_r + T1n_i + T1n_m; 
  T1d = T1d_s + T1d_r + T1d_i + T1d_m; 
   
  T2n = T2n_r + T2n_i + T2n_m; 
  T2d = T2d_r + T2d_i + T2d_m; 
   
  N = Sn + Su + Sipt +  Sd + Ln + Lu + Lipt + Ld + 
   In + Iu + Iipt + Id + 
   T1n + T1d + T2n + T2d + Sipt_postipt + Sd_postipt; 
   
  N_hiv = Su + Sipt +  Sd + Lu + Lipt + Ld + 
   Iu + Iipt + Id + 
   T1d + T2d + Sipt_postipt + Sd_postipt; 
   
  #################################### 
  # Force of infection by resistance type 
  #################################### 
   
  beta_h = b*beta_0; 
   
  lambda_s = (beta_h*(Iu_s + Iipt_s + Id_s + (1-gamma_s)*T1d_s) + 
  beta_0*(In_s + (1- gamma_s)*T1n_s))/N; 
   
  lambda_i = x_i*(beta_h*(Iu_i + Iipt_i + Id_i + (1-gamma_i1)*T1d_i +  
  (1-gamma_i2)*T2d_i) + beta_0*(In_i + (1-gamma_i1)*T1n_i +  
  (1-gamma_i2)*T2n_i))/N; 
    
  lambda_r = x_r*(beta_h*(Iu_r + Iipt_r + Id_r + (1-gamma_r1)*T1d_r +  
  (1-gamma_r2)*T2d_r) + beta_0*(In_r + (1-gamma_r1)*T1n_r +  
  (1-gamma_r2)*T2n_r))/N; 
	 97	
     
  lambda_m = x_m*(beta_h*(Iu_m + Iipt_m + Id_m +  
  (1-gamma_m1)*T1d_m + (1-gamma_m2)*T2d_m) +  
  beta_0*(In_m + (1-gamma_m1)*T1n_m + (1-gamma_m2)*T2n_m ))/N; 
     
    lambda = lambda_s + lambda_i + lambda_r + lambda_m; 
     
     
  #################################### 
  # Recruitment rate (age 15+) 
  #################################### 
   
    dCum_ARI = lambda; # force of infection per capita 
    dCum_ARI_s = lambda_s; 
    dCum_ARI_r = lambda_r; 
    dCum_ARI_i = lambda_i; 
    dCum_ARI_m = lambda_m; 
     
    year_15 = 1995 # assume starting code in 1980 
 
   # Cum_ARI is variable 54 
   if (times>year_15) { # if have run model for >15 years 
    # latent infections determined by force of infection over previous 15 years 
    Lambda_l = Lambda*(1-exp(-(Cum_ARI - lagvalue(times-15,54))))  
    Lambda_s = Lambda-Lambda_l 
    prop_s = Cum_ARI_s - lagvalue(times-15,55) 
    prop_r = Cum_ARI_r - lagvalue(times-15,56) 
    prop_i = Cum_ARI_i - lagvalue(times-15,57) 
    prop_m = Cum_ARI_m - lagvalue(times-15,58) 
   } else {  
    # assume were at equilibrium prevalence before starting code in 1980 
    Lambda_l = Lambda*(1-exp(-(Cum_ARI +  
    (year_15-times)*equil_prev*beta_0)))  
    Lambda_s = Lambda-Lambda_l 
    prop_s = Cum_ARI_s + (year_15-times)*equil_prev*beta_0 
    prop_r = Cum_ARI_r # no resistance prior to 1980 
    prop_i = Cum_ARI_i  
    prop_m = Cum_ARI_m  
   } 
      
   tot_prop <- prop_s + prop_r + prop_i + prop_m 
    
   # Assume everyone enters with only one strain, proportional to the 
   # amount that they have seen each 
   if (prop_s > 0) { 
   Lambda_ls <- prop_s/tot_prop*Lambda_l 
    } else {Lambda_ls<-0 
  } 
   if (prop_i > 0) { 
   Lambda_li <- prop_i/tot_prop*Lambda_l 
    } else {Lambda_li=0 
} 
   if (prop_r > 0) { 
   Lambda_lr <- prop_r/tot_prop*Lambda_l 
    } else {Lambda_lr=0 
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} 
   if (prop_m > 0) { 
   Lambda_lm <- prop_m/tot_prop*Lambda_l 
    } else {Lambda_lm=0 
} 
    
   
   
  #################################### 
  # TB susceptibles 
  #################################### 
   
  dSn = Sn*(-lambda - mu_0 - h) + Lambda_s 
   
  dSu = Su*(-lambda - mu_u - z) + h*Sn; 
   
  dSipt = Sipt*(-lambda_i - lambda_m - mu_i - w) + 
   theta_s*z*Su + theta_s*e*Sd; 
   
  dSd = Sd*(-lambda - mu_d) + (1 - theta_s)*z*Su +  
  w*Sipt  - theta_s*e*Sd; 
   
  # Strains cleared through IPT - also calling "S" 
   
  dSipt_postipt = gamma_lipt*(Lipt_s+Lipt_r) +  
  Sipt_postipt*(-m_ipt*lambda_i - m_ipt*lambda_m - mu_i - w) +  
  theta_s*e*Sd_postipt; 
   
  dSd_postipt = Sd_postipt*(-m_ipt*lambda - mu_d) + 
   w*Sipt_postipt - theta_s*e*Sd_postipt; 
   
  #################################### 
  # TB latently infected 
  #################################### 
 
  # HIV uninfected 
   
  dLn_s = Lambda_ls + (1-rho_0)*Sn*lambda_s  +  
   m_0*q_0*(Ln_s*(-lambda_r - rho_0*lambda_s) +  
   (1-rho_0)*Ln_r*lambda_s) + gamma_s*k_1*T1n_s + sigma*In_s + 
   Ln_s*(-tau_0 - mu_0 - h - m_0*(lambda_m + lambda_i)) ; 
   
  dLn_si = Ln_si*(-tau_0 - mu_0 - h) + 
  m_0*q_0*(Ln_si*(-lambda_r - lambda_i - lambda_m - rho_0*lambda_s) +  
  (1-rho_0)*(Ln_i + Ln_ri)*lambda_s) + 
  m_0*(1-q_0)*(-r*Ln_si*lambda_m + lambda_i*(Ln_s + r*Ln_sm)); 
   
  dLn_sm = Ln_sm*(-tau_0 - mu_0 - h) + 
  m_0*q_0*(Ln_sm*(-lambda_r - lambda_i - lambda_m - rho_0*lambda_s)  +  
  (1-rho_0)*(Ln_m + Ln_rm)*lambda_s) + 
   m_0*(1-q_0)*(-r*Ln_sm*lambda_i + lambda_m*(Ln_s + r*Ln_si)); 
   
  dLn_r = Lambda_lr + (1-rho_0)*Sn*lambda_r + gamma_r2*k_r*T2n_r -  
  m_0*Ln_r*(lambda_m + lambda_i) + 
  m_0*q_0*(Ln_r*(-lambda_s - rho_0*lambda_r) + (1-rho_0)*Ln_s*lambda_r) + 
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  Ln_r*(-tau_0 - mu_0 - h) + sigma*In_r + gamma_r1*k_1*T1n_r; 
   
  dLn_ri = Ln_ri*(-tau_0 - mu_0 - h) + 
  m_0*q_0*(Ln_ri*(-lambda_s - lambda_i - lambda_m - rho_0*lambda_r)  + 
  (1-rho_0)*(Ln_i + Ln_si)*lambda_r) +  
   m_0*(1-q_0)*(-r*Ln_ri*lambda_m + lambda_i*(Ln_r + r*Ln_rm)) ; 
   
  dLn_rm = Ln_rm*(-tau_0 - mu_0 - h) + 
  m_0*q_0*(Ln_rm* (-lambda_s - lambda_i - lambda_m - rho_0*lambda_r) +  
  (1-rho_0)*(Ln_m + Ln_sm)*lambda_r) + 
   m_0*(1-q_0)*(-r*Ln_rm*lambda_i + lambda_m*(Ln_r + r*Ln_ri)); 
   
  dLn_i = Lambda_li + (1-rho_0)*Sn*lambda_i +  
  m_0*q_0*((1-rho_0)*(Ln - Ln_i)*lambda_i +  gamma_i2*k_i*T2n_i + 
  Ln_i*(-lambda_s - lambda_r - lambda_m - rho_0*lambda_i)) + 
  Ln_i*(-tau_0 - mu_0 - h) + sigma*In_i + gamma_i1*k_1*T1n_i; 
   
  dLn_m = Lambda_lm + (1-rho_0)*Sn*lambda_m +  
  m_0*q_0*((1-rho_0)*(Ln - Ln_m)*lambda_m +  
  Ln_m*(- lambda_s - lambda_i - lambda_r - rho_0*lambda_m)) + 
  Ln_m*(-tau_0 - mu_0 - h) + sigma*In_m + gamma_m1*k_1*T1n_m +  
  gamma_m2*k_m*T2n_m; 
   
  # HIV undetected 
   
  dLu_s = (1-rho_u)*Su*lambda_s - m_u*Lu_s*(lambda_i + lambda_m) +  
  m_u*q_u*(Lu_s*(-lambda_r - rho_u*lambda_s) +  
  (1-rho_u)*Lu_r*lambda_s) + Lu_s*(-tau_u - mu_u - z) + h*Ln_s; 
   
  dLu_si = Lu_si*(-tau_u - mu_u - z) + h*Ln_si + 
  m_u*q_u*(Lu_si*(-lambda_r - lambda_i - lambda_m - rho_u*lambda_s) +  
  (1-rho_u)*(Lu_i + Lu_ri)*lambda_s) +  
  m_u*(1-q_u)*(-r*Lu_si*lambda_m  + lambda_i*(Lu_s + r*Lu_sm)); 
   
  dLu_sm = Lu_sm*(-tau_u - mu_u - z) + h*Ln_sm + 
  m_u*q_u*(Lu_sm*(-lambda_r - lambda_i - lambda_m - rho_u*lambda_s) +  
  (1-rho_u)*(Lu_m + Lu_rm)*lambda_s) + 
  m_u*(1-q_u)*(-r*Lu_sm*lambda_i  + lambda_m*(Lu_s + r*Lu_si)); 
   
  dLu_r = (1-rho_u)*Su*lambda_r - m_u*Lu_r*(lambda_m + lambda_i) + 
  m_u*q_u*(Lu_r*(-lambda_s - rho_u*lambda_r) + (1-rho_u)*Lu_s*lambda_r) + 
  Lu_r*(-tau_u - mu_u - z) + h*Ln_r; 
   
  dLu_ri =  Lu_ri*(-tau_u - mu_u - z) + 
  m_u*q_u*(Lu_ri*(-lambda_s - lambda_i - lambda_m -rho_u*lambda_r) +  
  (1-rho_u)*(Lu_i + Lu_si)*lambda_r) + h*Ln_ri + 
  m_u*(1-q_u)*(-r*Lu_ri*lambda_m  + lambda_i*(Lu_r + r*Lu_rm)); 
   
  dLu_rm =  Lu_rm*(-tau_u - mu_u - z) + 
  m_u*q_u*(Lu_rm*(-lambda_s - lambda_i - lambda_m -rho_u*lambda_r) +  
  (1-rho_u)*(Lu_m + Lu_sm)*lambda_r) + h*Ln_rm + 
  m_u*(1-q_u)*(-r*Lu_rm*lambda_i + lambda_m*(Lu_r + r*Lu_ri)); 
   
  dLu_i = (1-rho_u)*Su*lambda_i + Lu_i*(-tau_u - mu_u - z) + h*Ln_i + 
  m_u*q_u*((1-rho_u)*(Lu - Lu_i)*lambda_i +  
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  Lu_i*(-lambda_s - lambda_r - lambda_m - rho_u*lambda_i)); 
   
  dLu_m = (1-rho_u)*Su*lambda_m +Lu_m*(-tau_u - mu_u - z) + h*Ln_m + 
   m_u*q_u*((1-rho_u)*(Lu - Lu_m)*lambda_m +  
   Lu_m*(- lambda_s - lambda_i - lambda_r - rho_u*lambda_m)) ; 
   
  # on IPT   
  dLipt_s = -m_d*Lipt_s*(lambda_m +lambda_i) -  
  v*tau_d*Lipt_s - mu_i*Lipt_s + gamma_ipt*Iipt_s -  
  a_lipt*Lipt_s +  phi*gamma_s*k_1*T1d_s +  
  theta_l*z*Lu_s - w*Lipt_s - gamma_lipt*Lipt_s  + theta_l*e*Ld_s; 
   
  dLipt_r = -m_d*Lipt_r*(lambda_m +lambda_i) - v*tau_d*Lipt_r -  
  mu_i*Lipt_r + gamma_ipt*Iipt_r - a_lipt*Lipt_r +  
  phi*gamma_r1*k_1*T1d_r + theta_l*z*Lu_r - w*Lipt_r - 
   gamma_lipt*Lipt_r + phi*gamma_r2*k_r*T2d_r + theta_l*e*Ld_r; 
   
  dLipt_i = (1-rho_d)*Sipt*lambda_i +  
  (1-rho_d)*m_ipt*Sipt_postipt*lambda_i +  
  m_d*q_d*(1-rho_d)*(Lipt_r + Lipt_s + Lipt_m)*lambda_i +  
  m_d*(1-q_d)*(Lipt_r + Lipt_s)*lambda_i - m_d*q_d*Lipt_i*lambda_m -  
  m_d*q_d*rho_d*Lipt_i*lambda_i - tau_d*Lipt_i - mu_i*Lipt_i +  
  sigma_d*Iipt_i +a_lipt*Lipt_s + phi*gamma_i1*k_1*T1d_i +  
  theta_l*z*(Lu_i + Lu_si + Lu_ri) - w*Lipt_i  + theta_l*e*(Ld_i + Ld_si + Ld_ri); 
   
  dLipt_m = (1-rho_d)*Sipt*lambda_m +  
  (1-rho_d)*m_ipt*Sipt_postipt*lambda_m + 
  m_d*q_d*(1-rho_d)*(Lipt_r + Lipt_s + Lipt_i)*lambda_m  +  
  m_d*(1-q_d)*(Lipt_r + Lipt_s)*lambda_m - m_d*q_d*Lipt_m*lambda_i -  
  m_d*q_d*rho_d*Lipt_m*lambda_m - tau_d*Lipt_m - mu_i*Lipt_m +  
  sigma_d*Iipt_m + a_lipt*Lipt_r + phi*gamma_m1*k_1*T1d_m + 
   theta_l*z*(Lu_m + Lu_sm + Lu_rm) - 
    w*Lipt_m + theta_l*e*(Ld_m + Ld_sm + Ld_rm); 
   
  # HIV detected 
   
  dLd_s = (1-rho_d)*Sd*lambda_s - m_d*Ld_s*(lambda_i+lambda_m) +  
  (1-rho_d)*m_ipt*Sd_postipt*lambda_s + w*Lipt_s  - theta_l*e*Ld_s + 
  m_d*q_d*(Ld_s*(-lambda_r - rho_d*lambda_s) +  
  (1-rho_d)*Ld_r*lambda_s) + Ld_s*(-tau_d - mu_d) +  
  sigma_d*Id_s + k_1*(1-phi)*gamma_s*T1d_s + (1 - theta_l)*z*Lu_s; 
   
  dLd_si =  (1 - theta_l)*z*Lu_si - theta_l*e*Ld_si + 
  m_d*q_d*(Ld_si*(-lambda_r - lambda_i - lambda_m - rho_d*lambda_s) + 
   (1-rho_d)*(Ld_i+Ld_ri)*lambda_s) + Ld_si*(-tau_d - mu_d) + 
  m_d*(1-q_d)*(-r*Ld_si*lambda_m + lambda_i*(Ld_s + r*Ld_sm))  ; 
   
  dLd_sm =  (1 - theta_l)*z*Lu_sm - theta_l*e*Ld_sm + 
  m_d*q_d*(Ld_sm*(-lambda_r - lambda_i - lambda_m - rho_d*lambda_s) +  
  (1-rho_d)*(Ld_m+Ld_rm)*lambda_s) + Ld_sm*(-tau_d - mu_d) + 
  m_d*(1-q_d)*(-r*Ld_sm*lambda_i + lambda_m*(Ld_s + r*Ld_si)) ;  
   
  dLd_r = (1-rho_d)*Sd*lambda_r - m_d*Ld_r*(lambda_m+lambda_i) +  
  (1-rho_d)*m_ipt*Sd_postipt*lambda_r +  
  m_d*q_d*(Ld_r*(-lambda_s - rho_d*lambda_r) +  
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  (1-rho_d)*Ld_s*lambda_r) + (1-phi)*gamma_r2*k_r*T2d_r + 
  Ld_r*(-tau_d - mu_d) + sigma_d*Id_r + k_1*(1-phi)*gamma_r1*T1d_r +  
  (1 - theta_l)*z*Lu_r + w*Lipt_r - theta_l*e*Ld_r; 
   
  dLd_ri = (1 - theta_l)*z*Lu_ri - theta_l*e*Ld_ri + 
  m_d*q_d*(Ld_ri*(-lambda_s - lambda_i - lambda_m - rho_d*lambda_r) +  
  (1-rho_d)*(Ld_i+Ld_si)*lambda_r) + Ld_ri*(-tau_d - mu_d) + 
  m_d*(1-q_d)*(-r*Ld_ri*lambda_m  + lambda_i*(Ld_r + r*Ld_rm)); 
   
  dLd_rm = (1 - theta_l)*z*Lu_rm - theta_l*e*Ld_rm + 
  m_d*q_d*(Ld_rm*(-lambda_s - lambda_i - lambda_m - rho_d*lambda_r) +  
  (1-rho_d)*(Ld_m+Ld_sm)*lambda_r) + Ld_rm*(-tau_d - mu_d) + 
  m_d*(1-q_d)*(-r*Ld_rm*lambda_i + lambda_m*(Ld_r + r*Ld_ri)) ; 
   
  dLd_i = (1-rho_d)*Sd*lambda_i + (1 - theta_l)*z*Lu_i +  
  (1-rho_d)*m_ipt*Sd_postipt*lambda_i+  
  m_d*q_d*((1-rho_d)*(Ld - Ld_i)*lambda_i +  
  Ld_i*(-lambda_s - lambda_r - lambda_m - rho_d*lambda_i)) + 
  Ld_i*(-tau_d - mu_d) + sigma_d*Id_i + k_1*(1-phi)*gamma_i1*T1d_i +  
  w*Lipt_i + gamma_i2*k_i*T2d_i - theta_l*e*Ld_i; 
   
  dLd_m = (1-rho_d)*Sd*lambda_m + (1 - theta_l)*z*Lu_m +  
  (1-rho_d)*m_ipt*Sd_postipt*lambda_m+ 
  m_d*q_d*((1-rho_d)*(Ld - Ld_m)*lambda_m +  
  Ld_m*(- lambda_s - lambda_i - lambda_r -rho_d*lambda_m)) + 
  Ld_m*(-tau_d - mu_d) + sigma_d*Id_m + k_1*(1-phi)*gamma_m1*T1d_m +  
  w*Lipt_m + gamma_m2*k_m*T2d_m - theta_l*e*Ld_m; 
   
  #################################### 
  # Infectious 
  #################################### 
   
  # HIV negative 
   
  dIn_s = lambda_s*rho_0*(Sn + m_0*q_0*Ln) +  
  tau_0*(Ln_s + Ln_si + Ln_sm) + In_s*(-mu_t - c_0 - sigma -h) +  
  (1-epsilon)*k_1*(1-a_si-a_sr-a_sm)*(1-gamma_s)*T1n_s; 
   
  dIn_r = lambda_r*rho_0*(Sn + m_0*q_0*Ln) +  
  tau_0*(Ln_r + Ln_ri + Ln_rm) + In_r*(-mu_t - c_0 - sigma -h) +  
  (1-epsilon)*k_1*(a_sr*(1-gamma_s)*T1n_s +  
  (1-a_rm)*(1-gamma_r1)*T1n_r) + 
  (1-epsilon)*(1-a_si)*(1-gamma_r2)*k_r*T2n_r; 
   
  dIn_i = lambda_i*rho_0*(Sn + m_0*q_0*Ln) + tau_0*Ln_i +  
  In_i*(-mu_t - c_0 - sigma -h) +  
  (1-epsilon)*k_1*(a_si*(1-gamma_s)*T1n_s + 
  (1-a_im)*(1-gamma_i1)*T1n_i) + 
  (1-epsilon)*(1-a_sr)*(1-gamma_i2)*k_i*T2n_i; 
   
  dIn_m = lambda_m*rho_0*(Sn + m_0*q_0*Ln) + tau_0*Ln_m +  
  In_m*(-mu_t - c_0 - sigma -h) +  
  (1-epsilon)*k_1*((1-gamma_m1)*T1n_m + a_sm*(1-gamma_s)*T1n_s +  
  a_rm*(1-gamma_r1)*T1n_r + a_im*(1-gamma_i1)*T1n_i) +  
  (1-epsilon)*a_sr*(1-gamma_i2)*k_i*T2n_i +  
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  (1-epsilon)*a_si*(1-gamma_r2)*k_r*T2n_r +  
  (1-epsilon)*(1-gamma_m2)*k_m*T2n_m; 
   
 
  # HIV undetected 
   
  dIu_s = lambda_s*rho_u*(Su + m_u*q_u*Lu) +  
  tau_u*(Lu_s + Lu_si + Lu_sm) + Iu_s*(-mu_tu - c_u - z) + h*In_s; 
   
  dIu_r = lambda_r*rho_u*(Su + m_u*q_u*Lu) +  
  tau_u*(Lu_r + Lu_ri + Lu_rm) + Iu_r*(-mu_tu - c_u - z) + h*In_r; 
   
  dIu_i =  lambda_i*rho_u*(Su + m_u*q_u*Lu) + tau_u*Lu_i +  
  Iu_i*(-mu_tu - c_u - z) + h*In_i; 
   
  dIu_m = lambda_m*rho_u*(Su + m_u*q_u*Lu) + tau_u*Lu_m +  
  Iu_m*(-mu_tu - c_u - z) + h*In_m; 
   
   
  # on IPT 
   
  dIipt_s = v*tau_d*Lipt_s - mu_ti*Iipt_s - c_d*Iipt_s -  
  gamma_ipt*Iipt_s - a_ipt*Iipt_s + 
  (1-epsilon_i)*theta_l*z*Iu_s - w*Iipt_s +  
  phi*(1-epsilon)*(1-a_si-a_sr-a_sm)*(1-gamma_s)*k_1*T1d_s  +  
  (1-epsilon_i)*theta_l*e*Id_s; 
   
  dIipt_r = v*tau_d*Lipt_r - mu_ti*Iipt_r - c_d*Iipt_r -  
  gamma_ipt*Iipt_r - a_ipt*Iipt_r + (1-epsilon_i)*theta_l*z*Iu_r -  
  w*Iipt_r + phi*(1-epsilon)*a_sr*(1-gamma_s)*k_1*T1d_s + 
  phi*(1-epsilon)*(1-a_rm)*(1-gamma_r1)*k_1*T1d_r +  
  phi*(1-epsilon)*(1-a_si)*(1-gamma_r2)*k_r*T2d_r  +  
  (1-epsilon_i)*theta_l*e*Id_r; 
   
  dIipt_i = rho_d*Sipt*lambda_i + rho_d*m_ipt*Sipt_postipt*lambda_i +  
  m_d*q_d*rho_d*Lipt*lambda_i + tau_d*Lipt_i - 
  mu_td*Iipt_i - c_d*Iipt_i - sigma_d*Iipt_i + a_ipt*Iipt_s +  
  (1-epsilon_i)*theta_l*z*Iu_i - w*Iipt_i + 
  phi*(1-epsilon)*a_si*(1-gamma_s)*k_1*T1d_s +  
  phi*(1-epsilon)*(1-a_im)*(1-gamma_i1)*k_1*T1d_i  +  
  (1-epsilon_i)*theta_l*e*Id_i; 
   
  dIipt_m = rho_d*Sipt*lambda_m + rho_d*m_ipt*Sipt_postipt*lambda_m +  
  m_d*q_d*rho_d*Lipt*lambda_m + tau_d*Lipt_m - 
  mu_td*Iipt_m - c_d*Iipt_m - sigma_d*Iipt_m + a_ipt*Iipt_r +  
  (1-epsilon_i)*theta_l*z*Iu_m - w*Iipt_m + 
  phi*(1-epsilon)*(1-gamma_m1)*k_1*T1d_m +  
  phi*(1-epsilon)*a_sm*(1-gamma_s)*k_1*T1d_s + 
  phi*(1-epsilon)*a_rm*(1-gamma_r1)*k_1*T1d_r +  
  phi*(1-epsilon)*a_im*(1-gamma_i1)*k_1*T1d_i + 
  phi*(1-epsilon)*a_si*(1-gamma_r2)*k_r*T2d_r  +  
  (1-epsilon_i)*theta_l*e*Id_m; 
  
  # HIV detected 
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  dId_s = lambda_s*rho_d*(Sd + m_d*q_d*Ld + m_ipt*Sd_postipt) +  
  tau_d*(Ld_s + Ld_si + Ld_sm) + Id_s*(-mu_td - c_d - sigma_d) +  
  (1-phi)*(1-epsilon)*k_1*(1-a_si-a_sr-a_sm)*(1-gamma_s)*T1d_s + 
  (1-epsilon_i)*(1-theta_l)*z*Iu_s + w*Iipt_s  -  
  (1-epsilon_i)*theta_l*e*Id_s - epsilon_i*e*Id_s; 
   
  dId_r = lambda_r*rho_d*(Sd + m_d*q_d*Ld + m_ipt*Sd_postipt) +  
  tau_d*(Ld_r + Ld_ri + Ld_rm) + Id_r*(-mu_td - c_d - sigma_d) +  
  (1-phi)*(1-epsilon)*k_1*(a_sr*(1-gamma_s)*T1d_s + 
  (1-a_rm)*(1-gamma_r1)*T1d_r) + (1-epsilon_i)*(1-theta_l)*z*Iu_r+ 
  (1-phi)*(1-epsilon)*(1-a_si)*(1-gamma_r2)*k_r*T2d_r  -  
  (1-epsilon_i)*theta_l*e*Id_r - epsilon_i*e*Id_r + w*Iipt_r ; 
   
  dId_i =  lambda_i*rho_d*(Sd + m_d*q_d*Ld + m_ipt*Sd_postipt) +  
  tau_d*Ld_i + Id_i* (-mu_td - c_d - sigma_d) +  
  (1-phi)*(1-epsilon)*k_1*(a_si*(1-gamma_s)*T1d_s +  
  (1-a_im)*(1-gamma_i1)*T1d_i) + 
  (1-epsilon_i)*(1-theta_l)*z*Iu_i + w*Iipt_i +  
  (1-epsilon)*(1-a_sr)*(1-gamma_i2)*k_i*T2d_i  -  
  (1-epsilon_i)*theta_l*e*Id_i - epsilon_i*e*Id_i; 
   
  dId_m = lambda_m*rho_d*(Sd + m_d*q_d*Ld + m_ipt*Sd_postipt) +  
  tau_d*Ld_m + Id_m*(-mu_td - c_d - sigma_d) + 
  (1-phi)*(1-epsilon)*k_1*((1-gamma_m1)*T1d_m +  
  a_sm*(1-gamma_s)*T1d_s + a_rm*(1-gamma_r1)*T1d_r + 
  a_im*(1-gamma_i1)*T1d_i) + (1-epsilon_i)*(1-theta_l)*z*Iu_m+  
  w*Iipt_m + (1-epsilon)*a_sr*(1-gamma_i2)*k_i*T2d_i + 
  (1-phi)*(1-epsilon)*a_si*(1-gamma_r2)*k_r*T2d_r +  
  (1-epsilon)*(1-gamma_m2)*k_m*T2d_m -  
  (1-epsilon_i)*theta_l*e*Id_m - epsilon_i*e*Id_m; 
   
  #################################### 
  # Treated First-Line 
  #################################### 
   
  # HIV negative 
   
  dT1n_s = T1n_s*(-mu_ts - k_1) + c_0*In_s +  
  epsilon*k_1*(1-a_si-a_sr-a_sm)*(1-gamma_s)*T1n_s; 
   
  dT1n_r = T1n_r*(-mu_tr1 - k_1) + f_r*c_0*In_r  +  
  g_r*epsilon*k_1*(a_sr*(1-gamma_s)*T1n_s +  
  (1-a_rm)*(1-gamma_r1)*T1n_r); 
   
  dT1n_i = T1n_i*(-mu_ti1 - k_1) + f_i*c_0*In_i +  
  g_i*epsilon*k_1*(a_si*(1-gamma_s)*T1n_s +  
  (1-a_im)*(1-gamma_i1)*T1n_i); 
   
  dT1n_m = T1n_m*(-mu_t - k_1) + f_m*c_0*In_m  +  
  g_m*epsilon*k_1*((1-gamma_m1)*T1n_m + 
  a_sm*(1-gamma_s)*T1n_s + a_rm*(1-gamma_r1)*T1n_r +  
  a_im*(1-gamma_i1)*T1n_i)  
   
   
  # HIV detected 
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  dT1d_s = T1d_s*(-mu_ths - k_1 +  
  epsilon*(1-a_si-a_sr-a_sm)*(1-gamma_s)*k_1) +  
  c_d*(Id_s + Iipt_s) + c_u*Iu_s + epsilon_i*z*Iu_s +  
  epsilon_i*e*Id_s; 
   
  dT1d_r = T1d_r*(-mu_thr1 - k_1) +  
  f_r*(c_d*(Id_r + Iipt_r) + c_u*Iu_r)  + f_r*epsilon_i*z*Iu_r + 
  g_r*epsilon*k_1*(a_sr*(1-gamma_s)*T1d_s +  
  (1-a_rm)*(1-gamma_r1)*T1d_r) + f_r*epsilon_i*e*Id_r; 
   
  dT1d_i = T1d_i*(-mu_thi1 - k_1) +  
  f_i*(c_d*(Id_i + Iipt_i) + c_u*Iu_i) + f_i*epsilon_i*z*Iu_i + 
  g_i*epsilon*k_1*(a_si*(1-gamma_s)*T1d_s +  
  (1-a_im)*(1-gamma_i1)*T1d_i) + f_i*epsilon_i*e*Id_i; 
   
  dT1d_m = T1d_m*(-mu_td - k_1) +  
  f_m*(c_d*(Id_m + Iipt_m) + c_u*Iu_m)  + f_m*epsilon_i*z*Iu_m + 
  g_m*epsilon*k_1*((1-gamma_m1)*T1d_m +  
  a_sm*(1-gamma_s)*T1d_s + a_rm*(1-gamma_r1)*T1d_r +  
  a_im*(1-gamma_i1)*T1d_i) + f_m*epsilon_i*e*Id_m; 
   
   
  #################################### 
  # Treated Second-Line 
  #################################### 
   
  # HIV negative 
   
  dT2n_r = -mu_tr2*T2n_r + (1-f_r)*c_0*In_r - k_r*T2n_r +  
  (1-g_r)*epsilon*a_sr*(1-gamma_s)*k_1*T1n_s + 
  (1-g_r)*epsilon*(1-a_rm)*(1-gamma_r1)*k_1*T1n_r +  
  epsilon*(1-a_si)*(1-gamma_r2)*k_r*T2n_r; 
   
  dT2n_i = -mu_ti2*T2n_i + (1-f_i)*c_0*In_i - k_i*T2n_i +  
  (1-g_i)*epsilon*a_si*(1-gamma_s)*k_1*T1n_s + 
  (1-g_i)*epsilon*(1-a_im)*(1-gamma_i1)*k_1*T1n_i +  
  epsilon*(1-a_sr)*(1-gamma_i2)*k_i*T2n_i; 
   
  dT2n_m = -mu_tm2*T2n_m + (1-f_m)*c_0*In_m - k_m*T2n_m +  
  (1-g_m)*epsilon*(1-gamma_m1)*k_1*T1n_m + 
  (1-g_m)*epsilon*a_sm*(1-gamma_s)*k_1*T1n_s +  
  (1-g_m)*epsilon*a_rm*(1-gamma_r1)*k_1*T1n_r +  
  (1-g_m)*epsilon*a_im*(1-gamma_i1)*k_1*T1n_i +  
  epsilon*a_sr*(1-gamma_i2)*k_i*T2n_i + 
  epsilon*a_si*(1-gamma_r2)*k_r*T2n_r +  
  epsilon*(1-gamma_m2)*k_m*T2n_m; 
   
  # HIV detected 
   
  dT2d_r = -mu_thr2*T2d_r - k_r*T2d_r + 
  (1-f_r)*(c_d*Id_r + c_d*Iipt_r + c_u*Iu_r)  +  
  (1-g_r)*epsilon*a_sr*(1-gamma_s)*k_1*T1d_s +  
  (1-g_r)*epsilon*(1-a_rm)*(1-gamma_r1)*k_1*T1d_r +  
  epsilon*(1-a_si)*(1-gamma_r2)*k_r*T2d_r +  
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  (1-f_r)*epsilon_i*z*Iu_r + (1-f_r)*epsilon_i*e*Id_r; 
   
  dT2d_i = -mu_thi2*T2d_i  - k_i*T2d_i +  
  (1-f_i)*(c_d*Id_i + c_d*Iipt_i + c_u*Iu_i) +  
  (1-g_i)*epsilon*a_si*(1-gamma_s)*k_1*T1d_s +  
  (1-g_i)*epsilon*(1-a_im)*(1-gamma_i1)*k_1*T1d_i +  
  epsilon*(1-a_sr)*(1-gamma_i2)*k_i*T2d_i +  
  (1-f_i)*epsilon_i*z*Iu_i + (1-f_i)*epsilon_i*e*Id_i; 
   
  dT2d_m = -mu_thm2*T2d_m - k_m*T2d_m +  
  (1-f_m)*(c_d*Id_m + c_d*Iipt_m + c_u*Iu_m)  +  
  (1-g_m)*epsilon*(1-gamma_m1)*k_1*T1d_m +  
  (1-g_m)*epsilon*a_sm*(1-gamma_s)*k_1*T1d_s +  
  (1-g_m)*epsilon*a_rm*(1-gamma_r1)*k_1*T1d_r +  
  (1-g_m)*epsilon*a_im*(1-gamma_i1)*k_1*T1d_i +  
  epsilon*a_sr*(1-gamma_i2)*k_i*T2d_i +  
  epsilon*a_si*(1-gamma_r2)*k_r*T2d_r +  
  epsilon*(1-gamma_m2)*k_m*T2d_m +  
  (1-f_m)*epsilon_i*z*Iu_m  + (1-f_m)*epsilon_i*e*Id_m; 
   
   
  #################################### 
  # Mortality 
  ####################################  
      # HIV deaths 
   # ALL deaths to people with HIV 
   # Per 1000 people with HIV 
   if (N_hiv > 1) { 
   dM_hiv = (mu_u*(Su + Lu) + mu_i*(Sipt + Sipt_postipt + Lipt) + 
    mu_d*(Sd + Sd_postipt + Ld) + mu_tu*Iu +  
    mu_ti*(Iipt_s + Iipt_r) + mu_td*(Iipt_m + Iipt_i + Id + T1d_m) +  
    mu_ths*T1d_s + mu_thi1*T1d_i + mu_thr1*T1d_r +  
    mu_thr2*T2d_r + mu_thi2*T2d_i + mu_thm2*T2d_m)/N_hiv*1000 
   } else { 
    dM_hiv = 0 
   } 
    
  return(list(c(dSn, dSu, dSd, #3 
    dLn_s, dLn_si, dLn_sm, dLn_i, dLn_r, dLn_ri, dLn_rm, dLn_m, #11 
    dLu_s, dLu_si, dLu_sm, dLu_i, dLu_r, dLu_ri, dLu_rm, dLu_m, #19 
    dLd_s, dLd_si, dLd_sm, dLd_i, dLd_r, dLd_ri, dLd_rm, dLd_m, #27 
    dIn_s, dIn_r, dIn_i, dIn_m, #31 
    dIu_s, dIu_r, dIu_i, dIu_m, #35 
    dId_s, dId_r, dId_i, dId_m, #39 
    dT1n_s, dT1n_r, dT1n_i, dT1n_m, #43 
    dT1d_s, dT1d_r, dT1d_i, dT1d_m, #47 
    dT2n_r, dT2n_i, dT2n_m, #50 
    dT2d_r, dT2d_i, dT2d_m, #53 
    dCum_ARI, dCum_ARI_s, dCum_ARI_r, dCum_ARI_i, dCum_ARI_m, #58 
    dSipt, dLipt_s, dLipt_i, dLipt_r, dLipt_m, 
    dIipt_s, dIipt_r, dIipt_i, dIipt_m, 
    dSipt_postipt,dSd_postipt, dM_hiv)))  
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Parameter	 Distribution	 References/Explanation	Default	rate	on	bedaquiline	(vs.	OBR)	 Unif(-10%,+10%)	 [19,	20]	Risk	of	relapse	on	bedaquiline	(ratio	to	OBR)	 Unif(0·4,1)	 [15,	21,	16]		Median	time	to	culture	conversion	on	bedaquiline	(ratio	to	OBR)	
Unif(0·4,1)	 [8,	16-18,	22,	23]	
Bedaquiline-associated	mortality	rate	(addition	to	TB	or	background	mortality)	




















































































































































































































DST	Method	 All	MDR	 PreXDR+XDR	 XDR	Only	 None	
Conventional	(Baseline)	 36·0	(33·5,	38·7)	 35·1	(34·4,	35·8)	 34·9	(34·6,	35·2)	 34·8	
















%	Acquiring	 All	MDR	 PreXDR+XDR	 XDR	Only	 None	
BDQR	 5·88	(2·18,	9·45)	 3·91	(1·44,	6·29)	 3·50	(1·30,	5·62)	 0	
PreXDR	 2·50	(1·16,	6·43)	 7·66	 7·66	 7·66	
PreXDR+BDQR	 1·93	(0·39,	3·69)	 1·00	(0·16,	1·99)	 0	 0	
XDR	 2·56	(1·09,	7·68)	 6·59	(5·84,	8·94)	 9·82	 9·82	





Outcome	per	100	Initial	Patients	 All	MDR	 PreXDR+XDR	 XDR	Only	 None	
Number	of	Secondary	Cases	 14	(10,	17)	 17	(16,	18)	 18	(18,	19)	 19	
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Figure S3.1: Transitions between resistance levels. We assume individuals can only acquire resistance while






































Figure S3.2: Transitions between TB health states (top) and regimen type (bottom). In the top figure,
movements right indicate culture conversion or cure, while movements left indicate relapse. Only individuals
who are untreated and culture negative are at risk of relapse. Untreated individuals may self-cure from
active disease, but only long-term stable cures are counted. In the bottom figure, movements down indicate
stopping treatment (routinely or default). Movements up indicate starting treatment (if untreated) or
starting bedaquiline (if eligible and untreated or on OBR only). Changes in health status and regimen may
occur simultaneously within one time step.
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General Calculation Principles
Accounting for conditional probabilities
In constructing the model, the potential events for each week were modeled in sequence. For each weekly
cycle we gave priority to events in an order that reflected the way they would be recorded as treatment
outcomes. For example, for people receiving treatment we first we recorded all deaths. Those people who
did not die could end treatment routinely, or if not they could end treatment prematurely (default). We
assumed only patients who remained on treatment could have culture converted, and only those who did not
culture convert could have acquired resistance (to at most one drug per week). To account for ordering, we
input the probability of each event conditional on not experiencing any of the events earlier in the calculation
sequence that week.
Examples:
• Weekly probability of culture conversion - input conditional on not dying, defaulting, or finishing
treatment that week
• Weekly probability of stopping treatment routinely - conditional on not dying that week
• Weekly probability of default - conditional on not dying or stopping treatment routinely that week
Converting rates to weekly probabilities
To convert rates to weekly probabilities (p), we first converted them to rates per week. We then used the
following formula:
p = 1  exp( rate)
Examples:
• Added mortality BDQ (rate 5 per 100 person-years, weekly probability 0.00096)
Resistance and relapse probabilities
To convert the probability of acquiring resistance prior to death, conversion, default, or stopping treat-




pdie + pdefault + pstop + pconvert + pres
Examples:
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• Probability acquired BDQ resistance given XDR
• Probability acquired XDR given pre-XDR, not on BDQ
• All other acquired resistance parameters (but may include additional considerations below)
A similar equation was used to relate the weekly cure rate to the probability of moving from “culture
negative” (high risk of relapse immediately after treatment) to “stable cure” prior to death, default, or
stopping treatment.
Median time to culture conversion
Based on our literature review, we estimated the median time to culture conversion (if no one had died
or stopped treatment) to be approximately 13 weeks for people initially MDR, 18 weeks for people initially
pre-XDR, and 26 weeks for people initially XDR. We used TreeAge to estimate a weekly probability of
conversion based on these targets and our fixed weekly probabilities of acquiring pre-XDR and XDR TB.
To simplify our sensitivity analyses, we chose to consider the e↵ect of BDQ on the median time to culture
conversion if no one had died, stopped treatment, or acquired resistance. We did this by calculating the
weekly probabilities of conversion from above to the median time of culture conversion if no one had died,
stopped treatment, or acquired resistance. Our bedaquiline multiplier was then applied to these values.
We converted median time to event parameters (in weeks) to weekly probabilities using the geometric
distribution:
P = 1  2 1/M
Probability acquiring pre-XDR without BDQ
From the literature, we estimated that the probability of acquiring resistance to any fluoroquinolone given
initial MDR was approximately 0.065, and that the probability of acquiring resistance to any second-line
injectable was similar. We also determined that the risk of XDR given pre-XDR was approximately 0.26.
Note the informal notation: P (PreXDR|MDR) is the probability of developing at least PreXDR for an
individual who is initially MDR, and not receiving bedaquiline.
P (PreXDR|MDR) = P (FQR|MDR) + P (2LIR|MDR)  P (XDR|MDR)
P (PreXDR|MDR) = P (FQR|MDR) + P (2LIR|MDR)  P (PreXDR|MDR)P (XDR|PreXDR)
P (PreXDR|MDR) = .065 ⇤ 2  0.26 ⇤ P (PreXDR|MDR)
P (PreXDR|MDR) = 0.103
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Probability acquiring pre-XDR with BDQ
This is similar to the section above, except we also need to account for the potential to acquire resistance
to bedaquiline. Note the informal notation: P (PreXDR|MDR) is the probability of developing at least
PreXDR for an individual who is initially MDR (and BDQ sensitive), on bedaquiline.
P (PreXDR|MDR) = P (FQR|MDR) + P (2LIR|MDR)  P (XDR|MDR)
P (PreXDR|MDR) = P (FQR|MDR)+P (2LIR|MDR) P (PreXDR|MDR)P (XDR|developPreXDR)
The issue here is that P (XDR|developPreXDR) depends on whether the individual already has resis-
tance to BDQ at the time they become PreXDR or not.
P (XDR|developPreXDR) = P (already BDQR|developPreXDR)P (XDR|PreXDR,BDQR)
+ (1  P (already BDQR|developPreXDR))P (XDR|PreXDR,BDQS)
To solve for P (already BDQR|developPreXDR), we can use our knowledge of the risk of resistance to
bedaquiline for people who are initially MDR vs preXDR.
P (BDQR|MDR) = P (BDQRprior to/without PreXDR)
+ (1  P (already BDQR|developPreXDR))P (PreXDR|BDQS,MDR)P (BDQR|PreXDR,BDQS)
P (already BDQR|developPreXDR) = P (BDQRprior to/without PreXDR)P (PreXDR|MDR,BDQR)
P (PreXDR|MDR)
Let X be the probability of developing bedaquiline resistance either prior to or without developing pre-
XDR for people initially MDR on BDQ. Let Y be the probability of ever developing pre-XDR for people
initially MDR on BDQ.
Let Qfm be the probability of ever developing FQ resistance given MDR on BDQ. Let Qxpb be the
probability of ever developing XDR given pre-XDR and BDQ resistance. Let Qxp be the probability of ever
developing XDR given pre-XDR and BDQ sensitivity. Let Qbm be the probability of developing bedaquiline
resistance given initially MDR and BDQ sensitive. Let Qbp be the probability of developing bedaquiline
resistance given initially pre-XDR and BDQ sensitive. Let Qpmb be the probability of developing pre-XDR
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given initially MDR and bedaquiline resistant.








Qbm = X + (1  XQpmb
Y
)Y Qbp
Solving the first equation for X:
Qbm   Y Qbp = X  XQpmbQbp
Qbm   Y Qbp = X(1 QpmbQbp)
Qbm   Y Qbp
1 QpmbQbp = X
Substituting into the first equation:








Y = 2Qfm  XQxpbQpmb   Y Qxp +XQxpQpmb
Y = 2Qfm  XQpmb(Qxpb  Qxp)  Y Qxp
Y = 2Qfm   Qbm   Y Qbp
1 QpmbQbpQpmb(Qxpb  Qxp)  Y Qxp
We used Matlab’s symbolic toolbox to solve this equation for Y. We checked this equation by verifying
that our TreeAge model gave similar results for X and the probability of developing XDR given initially
MDR and BDQ sensitive for a typical parameter set.
Probability acquiring XDR or BDQ resistance - from pre-XDR receiving BDQ
People can develop XDR without or prior to developing BDQ resistance, or they can acquire BDQ
resistance first, increasing their chances of developing XDR. Similarly people can develop BDQ resistance
without, prior to, or after developing XDR.
Let X be the weekly probability of developing BDQ resistance given pre-XDR. Let Y be the weekly
probability of developing XDR given pre-XDR. Let A be the weekly probability of any other possible event
(probability of dying or defaulting or finishing treatment or culture converting).
Let Qbp be the probability of ever developing BDQ resistance starting pre-XDR, on BDQ. Let Qxp be the
probability of ever developing XDR starting pre-XDR, BDQ-sensitive, on BDQ. Let Qbx be the probability
142
of ever developing BDQ resistance starting XDR. Let Qxpb be the proportion of people with pre-XDR and
BDQ resistance who acquire XDR prior to death, default, finishing treatment, or culture conversion.
We can then use the following equations to solve for X and Y .
Qbp =
X
X + Y +A
+Qbx
Y
X + Y +A
Qxp =
Y
X + Y +A
+Qxbp
X
X + Y +A
Therefore
Qbp(X + Y +A) = X +QbxY
Qxp(X + Y +A) = Y +QxbpX
Solving for X first:




Plugging into the equation for Y:
Qxp(X + Y +A) = Y +QxbpX


















Qbp   1 = Y
✓




QxpA(Qbp   1)  (Qxp  Qxbp)QbpA
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